Revance Therapeutics Inc  

(Public, NASDAQ:RVNC)   Watch this stock  
Find more results for DANIEL C HERBERT, MD
31.77
-0.21 (-0.66%)
Jul 1 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 31.57 - 33.01
52 week 14.02 - 35.72
Open 32.39
Vol / Avg. 0.00/284,958.00
Mkt cap 765.81M
P/E     -
Div/yield     -
EPS -2.54
Shares 23.95M
Beta     -
Inst. own 104%
Aug 10, 2015
Q2 2015 Revance Therapeutics Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Jun 10, 2015
Revance Therapeutics Inc at William Blair Annual Growth Stock Conference
Jun 4, 2015
Revance Therapeutics Inc at Jefferies Global Healthcare Conference
May 13, 2015
Q1 2015 Revance Therapeutics Inc Earnings Call - Webcast
May 13, 2015
Q1 2015 Revance Therapeutics Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '15) 2014
Net profit margin -20536.00% -16427.42%
Operating margin -20233.33% -13590.08%
EBITD margin - -13054.57%
Return on average assets -33.56% -58.50%
Return on average equity -36.36% -668.62%
Employees 83 -
CDP Score - -

Address

7555 Gateway Blvd
NEWARK, CA 94560-1152
United States - Map
+1-510-7423400 (Phone)
+1-510-7423401 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Revance Therapeutics, Inc. is a clinical-stage specialty biopharmaceutical company. The Company is focused on the development, manufacturing and commercialization of botulinum toxin products for multiple aesthetic and therapeutic indications. Its TransMTS technology enables delivery of botulinum toxin type A through two dose formulations, topical product candidate RT001 and injectable product candidate RT002. RT001 is a non-injectable dose form. RT001 is being studied for aesthetic indications, such as crow's feet lines (wrinkles around the eyes) and therapeutic indications, such as hyperhidrosis (excessive sweating). It is in a Phase III development program of RT001 in North America for the treatment of crow's feet lines. RT002 is an injectable formulation of botulinum toxin designed to be targeted and longer lasting. RT002 is being studied for aesthetic indications, such as glabellar (frown) lines and therapeutic uses, such as muscle movement disorders.

Officers and directors

Angus C. Russell Independent Chairman of the Board
Age: 59
Bio & Compensation  - Reuters
Dan L. Browne Co-Founder, President, Chief Executive Officer, Director
Age: 53
Bio & Compensation  - Reuters
Jacob Martin Waugh M.D. Co-Founder, Chief Scientific Officer
Age: 44
Bio & Compensation  - Reuters
Lauren P. Silvernail Chief Financial Officer, Executive Vice President of Corporate Development
Age: 56
Bio & Compensation  - Reuters
Arthur P. Bertolino M.D., Ph.D. Executive Vice President, Chief Medical Officer
Age: 60
Bio & Compensation  - Reuters
Curtis L. Ruegg Ph.D. Executive Vice President of Research and Development
Age: 46
Bio & Compensation  - Reuters
Sharon Hall Vice President of Regulatory Affairs
Bio & Compensation  - Reuters
Jeanie D. Herbert Senior Director of Investor Relations
Bio & Compensation  - Reuters
Phil J. Vickers Director
Age: 55
Bio & Compensation  - Reuters
Bob Byrnes Independent Director
Age: 70
Bio & Compensation  - Reuters